Use of Magtrace as an Alternative Approach in Staging the Axilla in Early-Stage Breast Cancer: A Single-Center Experience
2024

Using Magtrace for Breast Cancer Staging

Sample size: 60 publication Evidence: moderate

Author Information

Author(s): Muacevic Alexander, Adler John R, Oweis Rami, Anil Aditya, Marinov Alexander, Hamati Tawfiq, Masudi Tahir

Primary Institution: The Rotherham NHS Foundation Trust

Hypothesis

Is the new Magtrace technique equivalent to the gold standard 99mTc technique for staging the axilla in early-stage breast cancer?

Conclusion

Magtrace is comparable to the standard technique in terms of practicality and risk of complications, with potential cost benefits.

Supporting Evidence

  • The detection rate of SLNB was higher in the 99mTc group compared to the Magtrace group.
  • Both groups had a similar number of lymph nodes retrieved during the procedure.
  • The average duration of the surgical procedure was longer for the Magtrace group.

Takeaway

Doctors are testing a new method called Magtrace to see if it works as well as the old method for checking breast cancer spread, and it seems to do just as good a job.

Methodology

A single-center retrospective study comparing Magtrace and 99mTc techniques in 60 patients undergoing SLNB.

Limitations

The study has a small sample size and is retrospective in design.

Participant Demographics

Mean age of participants was 64.25 years, with a mix of tumor stages and histopathologies.

Statistical Information

P-Value

p=0.012

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.7759/cureus.75015

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication